Fluoroazomycin arabinoside F-18
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Fluoroazomycin arabinoside F-18
- DrugBank Accession Number
- DB15134
- Background
Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 246.185
Monoisotopic: 246.062983101 - Chemical Formula
- C8H10FN3O5
- Synonyms
- 18F-FAZA
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- UG7I3Y42PV
- CAS number
- 864084-85-5
- InChI Key
- LPZSRGRDVVGMMX-FJBGPTLJSA-N
- InChI
- InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1/i9-1
- IUPAC Name
- (2S,3S,4S,5S)-2-[(¹⁸F)fluoromethyl]-5-(2-nitro-1H-imidazol-1-yl)oxolane-3,4-diol
- SMILES
- O[C@H]1[C@H](O)[C@H](O[C@@H]1C[18F])N1C=CN=C1[N+]([O-])=O
References
- General References
- Not Available
- External Links
- ChemSpider
- 2104828
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Terminated Diagnostic Breast Neoplasms 1 1 Enrolling by Invitation Diagnostic Non-Rhabdo. Soft Tissue Sarcoma / Rhabdomyosarcomas 1 1, 2 Terminated Diagnostic Neuroendocrine Tumors / Renal Cell Carcinoma (RCC) 1 Not Available Completed Not Available Aggressive, recurrent Non-Hodgkin Lymphoma / Aggressive, refractory Non-Hodgkin's Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent High Grade B-Cell Lymphoma / Recurrent Malignant Neoplasm / Recurrent Plasma Cell Myeloma / Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B Cell Lymphoma (DLBCL) / Refractory High Grade B-cell Lymphoma (HGBCL) / Refractory Malignant Neoplasm / Refractory Plasma Cell Myeloma / Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma 1 Not Available Recruiting Diagnostic Pancreatic Adenocarcinoma Locally Advanced / Pancreatic Adenocarcinoma Non-resectable / Unresectable Pancreatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 13.0 mg/mL ALOGPS logP -0.45 ALOGPS logP -0.19 Chemaxon logS -1.3 ALOGPS pKa (Strongest Acidic) 12.45 Chemaxon pKa (Strongest Basic) -0.016 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 6 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 110.65 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 49.71 m3·mol-1 Chemaxon Polarizability 20.67 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at May 20, 2019 14:52 / Updated at June 12, 2020 16:53